Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking method to diabetes management. These innovative drugs work by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to consumption. By triggering GLP-1 receptors in the pancreas, these compounds boost insulin release and suppress glucagon

The burgeoning landscape of innovative treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting substantial weight loss – they exhibit intriguing variations in their